ÁÙ´²ÑÀÖܲ¡Ñ§(ÖÐÎÄ°æ)Ò©ÎïÐÔÑÀö¸ÔöÉúµÄÖÎÁÆר¼­

Ŀ¼Contents ¾­µäÎÄÏ× Classic Literatures ´ÓÒ©ÎïÐÔÑÀö¸ÔöÉú»¼ÕßÈýά×ø±êÊý¾Ý·ÖÎöÑÀö¸ÐÎ̬ µÄ¸Ä±ä……………………………………………… 1 Analysis of changes in gingival contour from threedimensional co-ordinate data in subjects with drug-induced gingival overgrowth Thomason JM, Ellis JS, Jovanovski V, Corson M, Lynch E, Seymour RA èïÇìÏÈ Éó Õž®È» Òë ±½Í×Ó¢ÓÕµ¼µÄÑÀö¸ÔöÉúµÄÓ°ÏìÒòËØ………………… 6 Factors influencing phenytoin-induced gingival enlargement Majola MP, McFadyen ML, Connolly C, Nair YP, Govender M Õ½õ²Å Éó ¶­äìäì Òë Ò©ÎïÐÔÑÀö¸ÔöÉúµÄ·çÏÕÒòËØ……………………… 13 Risk factors for drug-induced gingival overgrowth Seymour RA, Ellis JS, Thomason JM Õ½õ²Å Éó ÍòÅô Òë ÑÀÖܼ²²¡»¼ÕßʹÓøÆÀë×ÓͨµÀÞ׿¹¼ÁÒýÆðÑÀö¸ÔöÉú µÄ´¦Àí¡¢´¦·½ÓÃÒ©¡¢ÖÎÁÆ·´Ó¦ÒÔ¼°¶îÍ⻨·Ñ…… 17 Management of periodontal disease in patients using calcium channel blockers – gingival overgrowth, prescribed medications, treatment responses and added treatment costs Fardal Ø, Lygre H èïÇìÏÈ Éó Ôø¼Ñ¿¥ Òë ÑÀÖÜÖÎÁƶÔÓÚ»·æßËØAÓÕµ¼µÄÑÀö¸ÔöÉúÑÏÖØ³Ì¶ÈµÄ ÓÐЧÐÔ………………………………………………… 22 Effectiveness of periodontal therapy on the severity of cyclosporin A-induced gingival overgrowth Aimetti M, Romano F, Debernardi C Õ½õ²Å Éó ¶­äìäì Òë ¸ÆÀë×ÓͨµÀÞ׿¹¼ÁÓëÑÀö¸ÔöÉúµÄÏ໥¹Øϵ………… 27 Association between calcium channel blockers and gingival hyperplasia Kaur G, Verhamme KMC, Dieleman JP, Vanrolleghem A, van Soest EM, Stricker BHCh, Sturkenboom MCJM èïÇìÏÈ Éó ÍõÑÓ·å Òë ÕªÒª Abstracts ½ÓÊÜÏõ±½µØƽºÍµØ¶ûÁòÖÎÁƵĻ¼ÕßÔÚ¶ÔÒòÑÀÖÜÖÎ ÁƺóÑÀö¸ºÍÑÀÖÜÇé¿öµÄÆÀ¹À*… …………………… 32 Evaluation of gingival and periodontal conditions following causal periodontal treatment in patients treated with nifedipine and diltiazem* BuHon P. Machuca G. Martinez-SahuquiUo A. Rios JV. Velasco E. Rojas J. LacaJle JR Õ½õ²Å Éó ¶­äìäì Òë 3ÖÖ²»Í¬ÊÖÊõ·½·¨ÖÎÁÆÒ©ÎïÐÔÑÀö¸ÔöÉúµÄÁÆЧ¹Û²ì… 32 The efficacy of three different surgical techniques in the management of drug-induced gingival overgrowth Mavrogiannis M, Ellis JS, Seymour RA, Thomason JM Õ½õ²Å Éó ¶­äìäì Òë ¸÷ÖÖÒ©Îï¶Ô½ÓÊܶàÖÖÒ©ÎïÖÎÁƵijÉÄêºÍÉÙÄêÉöÒÆÖ² »¼ÕßÑÀö¸ÔöÉúµÄ·Ö±ðÓ°Ïì………………………… 33 Contribution of individual drugs to gingival overgrowth in adult and juvenile renal transplant patients treated with multiple therapy Wilson RF, Morel A, Smith D, Koffman CG, Ogg CS, Rigden SPA, Ashley FP Õ½õ²Å Éó ¶­äìäì Òë ½ÓÊܵضûÁò»òάÀ­ÅÁÃ×ÖÎÁÆ»¼ÕßµÄÑÀö¸ÔöÉú»¼²¡ ÂʺͷçÏÕ…………………………………………… 33 Prevalence and risk of gingival overgrowth in patients treated with diltiazem or verapamil Miranda J, Brunet L, Roset P, Berini L, FarréM, Mendieta C Õ½õ²Å Éó ¶­äìäì Òë Ïõ±½µØƽÒýÆðÑÀö¸ÔöÉúµÄ·¢ÉúÂʺÍÑÏÖس̶ȅ…… 34 The incidence and severity of nifedipine-induced gingival overgrowth Barclay S, Thomason JM, Idle JR and Seymour RA èïÇìÏÈ Éó ÀîÑ© Òë ÆÀ¹À»·æßËØAÒýÆðÑÀö¸ÔöÉúµÄסԺ»¼ÕßÖÐHLA¾ö¶¨ ´ØµÄ·Ö²¼ÆµÂÊ……………………………………… 34 Evaluation of the frequency of HLA determinants in patients with gingival overgrowth induced by cyclosporine-A Ceheci I, Kamarci A, Firatli E, Aygun S, Tanyeri H, Aydin AE, Çarin M. Güç U, Tuncer Ö èïÇìÏÈ Éó ÀîÑ© Òë Ó°ÏìÆ÷¹ÙÒÆÖ²»¼ÕßÑÀö¸ÔöÉú³Ì¶ÈµÄΣÏÕÒòËØÆÀ¹À HLA±íÐ͵Ä×÷ÓÃ……………………………………… 35 Determinants of gingival overgrowth severity in organ transplant patients An examination of the role of HLA phenotype Thomason JM. Seymour R.4. Ellis JS. Kelly PJ. Parry G. Dark J. Wilkin.son R, Ilde JR èïÇìÏÈ Éó ÀîÑ© Òë ÒÆֲǰÑÀö¸ÔöÉú¿ÉÔ¤²â»·æßËØÒýÆðÉöÒÆÖ²»¼ÕßÑÀö¸ ÑÏÖØÔöÉú……………………………………………… 35 Pre-transplant gingival hyperplasia predicts severe cyclosporin-induced gingival overgrowth in renal transplant patients Varga E. Lennon MA, Mair LH èïÇìÏÈ Éó ÀîÑ© Òë Ò©ÎïÐÔÑÀö¸ÔöÉú£ºÒ»Ïî¶Ô·¨¹úÒ©Îﾯ½äÊý¾Ý¿âµÄÑо¿… 36 Drug-induced gingival overgrowth: a study in the French Pharmacovigilance Database Bondon-Guitton E, Bagheri H, Montastruc J-L Õ½õ²Å Éó ÍòÅô Òë ÉöÒÆÖ²Êõºó·þÓû·æßËØAµÄ»¼ÕßµÄIL-1A»ùÒò¶à̬ÐÔÓë ÑÀö¸ÔöÉúµÄ¹Øϵ……………………………………… 36 Relationship between IL-1A polymorphisms and gingival overgrowth in renal transplant recipients receiving Cyclosporin A Bostanci N, Ilgenli T, Pirhan DC, Clarke FM, Marcenes W, Atilla G, Hughes FJ, McKay IJ Õ½õ²Å Éó ÍòÅô Òë Ò¶Ëá¶Ô±½Í×Ó¢ÐÔÑÀö¸ÔöÉúµÄ×÷ÓÃ………………… 37 Effect of folate on phenytoin hyperplasia Drew HJ. Vogel RI. Mohfsky W. Baker H and Frank O Õ½õ²Å Éó ÍòÅô Òë Æ÷¹ÙÒÆÖ²ºóÓ¦ÓÃÃâÒßÒÖÖƼÁËû¿ËĪ˾µÄ»¼ÕßÑÀö¸Ôö ÉúµÄ»¼²¡ÂÊ…………………………………………… 37 Prevalence of gingival overgrowth in transplant patients immunosuppressed with tacrolimus Ellis JS, Seymour RA, Taylor JJ, Thomason JM Õ½õ²Å Éó ÍòÅô Òë